Human Genome: Journal Reviews Lupus Drug Endpoints Positively

Human Genome announces a publication by the journal Arthritis Care & Research of an article describing the development and use of a novel evidence-based systemic lupus erythematosus (SLE) Responder Index selected as the primary endpoint of two pivotal Phase III clinical trials of BENLYSTA in serologically active patients with SLE.
MSN